Why Peter Lynch may take an interest in GENMAB A/S -SP ADR (NASDAQ:GMAB)

With a strategy that emphasized steady earnings growth and a strong market position, Peter Lynch sought out long-term winners. We put GENMAB A/S -SP ADR (NASDAQ:GMAB) to the test against his stock-picking rules.

Does GENMAB A/S -SP ADR (NASDAQ:GMAB) meet Peter Lynch’s stock-picking criteria?

• In terms of Return on Equity(ROE), GMAB is performing well, achieving a 21.38% ratio. This highlights the company's effective allocation of shareholder investments and signifies its commitment to maximizing returns.
• GMAB exhibits a favorable Debt-to-Equity ratio at 0.03. This highlights the company's ability to limit excessive debt levels and maintain a strong equity base, demonstrating its financial stability and risk management practices.
• Over the past 5 years, GMAB has demonstrated 29.12 growth in EPS, signifying its positive financial trajectory and potential for future profitability.
• With a PEG ratio of 0.36, GMAB appears to be fairly valued given its strong growth prospects.
• GMAB's Current Ratio of 5.25 reflects a strong ability to manage short-term financial commitments.

What else is there to say on the fundamentals of GMAB?

Every day ChartMill assigns a Fundamental Rating to every stock. The score ranges from 0 to 10 and is determined by evaluating multiple fundamental indicators and properties.

Overall GMAB gets a fundamental rating of 7 out of 10. We evaluated GMAB against 568 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making GMAB a very profitable company, without any liquidiy or solvency issues. GMAB is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make GMAB suitable for value and growth and quality investing!

For an up to date full fundamental analysis you can check the fundamental report of GMAB

Our Peter Lynch screener lists more Affordable Growth stocks and is updated daily.

Disclaimer

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.